Acute myeloid leukemia (AML) is a heterogeneous group of diseases resulting 14 from clonal transformation of hematopoietic precursors through the acquisition of 15 chromosomal rearrangements and multiple gene mutations. Accumulating evidence 16 has indicated that aberrantly expressed circular RNAs (circRNAs) are involved in 17 cancer development and progression. However, their clinical values and biological 18 roles in AML remain unclear. In this study, we identified the aberrantly 19 down-regulated profile of hsa_circ_0001947 in AML through microarray analysis and 20 validated it with quantitative reverse transcription polymerase chain reaction 21 (qRT-PCR). Then, we explored the clinical significance, biological functions and 22 regulatory mechanisms of hsa_circ_0001947 in AML patients. The results showed 23 that lower hsa_circ_0001947 expression was positively correlated with higher 24 2 leukemia cells in bone marrow or peripheral blood, indicating poor prognosis. Further, 25 bioinformatics analysis demonstrated hsa_circ_0001947-hsa-miR-329-5p-CREBRF 26 network. Down-regulation of hsa_circ_0001947 by siRNA promoted cell proliferation, 27 inhibited apoptosis, reduced drug resistance of AML cells, and also decreased the 28 expression of its targeted gene, CREBRF. The mimics of hsa-miR-329-5p reduced 29 drug resistance and decreased the expression of CREBRF, while its inhibitor 30 manifested anti-leukemia effects and increased CREBRF expression. In vivo studies 31 revealed that silencing hsa_circ_0001947 promoted the tumor growth in BALB/c 32 nude mice. Collectively, our findings suggest that hsa_circ_0001947 functions as a 33 tumor inhibitor to suppress AML cell proliferation through hsa-miR-329-5p/CREBRF 34 axis, which would be a novel target for AML therapy. 35 CREBRF; therapy. 37 38 Recently it has been considered as the latest research hotspot in the field of RNAs[6]. 47 Unlike the traditional linear RNAs (containing 5'and 3' ends), circRNAs have a closed 48 continuous loops, which are difficult to be degraded by RNA exonuclease and are 49 3 more stable in expression [6-8]. The most common method of circRNAs biogenesis is 50 through backsplicing, in which the 5' splice site (5'ss) of a downstream exon is paired 51 with the 3'ss of an upstream exon[3]. Backsplicing can occur in both linear 52 pre-mRNAs and within lariat intermediates harboring skipped exons[9, 10]. 53 CircRNAs were reported to be cell-specific, which are relatively abundant in the brain 54 and exist in human body fluids such as blood[11]. The relationship between circRNAs 55 and linear RNA isoforms was complicated. There are reports that circRNAs are 56 produced in competition with linear RNAs[12]. However, it was also reported that 57 there is no definite correlation between circRNAs and liner RNAs[13]. CircRNAs 58 contain plenty of microRNA (miRNA) binding sites, which offer itself an important 59 role as the miRNAs sponge in cells. Through the function of binding certain miRNAs, 60 circRNA could eliminate the inhibitory effect of miRNAs on its target genes, thereby 61 increasing the expression level of the target genes[7]. This mechanism is called 62 competitive endogenous RNA (ceRNA)[7, 8]. Moreover, circRNAs are suggested to 63 carry out diverse functions including sequestration and trafficking of proteins, 64 regulation of transcription and generation of short proteins [14-16]. 65 By interacting with disease-associated miRNAs, circRNAs play a significant 66 regulatory role in various diseases, from which the tumor-related research caught our 67 great attention. It has been reported that circTADA2As serve as miR-203a-3p sponge 68 to suppress breast cancer progression and metastasis[17], and circPSMC3 is a sponge 69 of miR-296-5p to suppress the proliferation and metastasis of gastric cancer by acting 70 as a ceRNA[18]. In addition, circOMA1 mediated the miR-145-5p suppresses of 71 tumor growth in nonfunctioning pituitary adenomas[19]. These findings indicate that 72 circRNAs could be a promising new diagnostic markers and treatment targets in solid 73 tumors. 74 4 However, there are rare data about the role of circRNAs in hematological 75 diseases, especially in the AML until now. It was reported that silencing of 76 circ_0009910 inhibits acute myeloid leukemia cell growth through increasing 77 miR-20a-5p[20]. Moreover, we have proven that hsa_circ_0004277 could be 78 characterized as a new biomarker and treatment target for AML via circRNAs profile 79 and bioinformatics analysis. In particular, we found chemotherapy could significantly 80 (BMMCs) from BM aspirates were separated by Lymphocyte Separation Medium 100 (TBD, China) density gradient centrifugation. BMMCs from 6 AML patients and 4 101 controls were used for the circRNA microarray, and all the 120 samples were used for 102 further detection or functional investigation. 103 Cell culture 104 THP-1 and 293T cells were commercially obtained from the Cell Bank of Type 105 Culture of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured 106 in RPMI-1640 (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, 107 Biological Industries, Beit HaEmek, Israel) in a humidified atmosphere at 37℃ and 108 5% CO2.
Introduction
Acute myeloid leukemia (AML) is characterized by blocked accumulation of 40 clonal myeloid progenitor cells and exhibits complex clinical and biological 41 heterogeneity [1] . Although great efforts have made in AML, the prognosis of AML is 42 still poor and its 5-year survival rate is only 25% [2] . It is of clinical significance to 43 explore the pathogenesis and identify new targets for AML. Circular RNAs 44 (circRNAs) are a widely expressed class of non-coding RNAs generated in a diverse 45 set of eukaryotic organisms, including animals, plants, yeasts and protists [3] [4] [5] . 46 restore the expression of hsa_circ_0004277, indicating the increasing level of 81 hsa_circ_0004277 was associated with successful treatment [21] . However, the 82 detailed mechanism of circRNAs in the pathogenesis of AML is still unclear. 83 To better demonstrate the expression profile of circRNAs in AML, we performed 84 a circRNA microarray in AML patients and healthy controls and presented an 85 AML-specific circRNA feature. We identified that the hsa_circ_0001947 was one of 86 the critical circRNAs that are frequently down-regulated in the bone marrow of AML 87 patients. Then with the help of bioinformatics analysis, a detailed 88 circRNA-miRNA-mRNA interaction network was described for hsa_circ_0001947. 89 What's more, in vitro and in vivo experiments showed that hsa_circ_0001947 could 90 inhibit the progress of AML. Overall, our study demonstrates that hsa_circ_0001947 91 exerts critical regulatory role in the AML and may serve as a potential therapeutic 92 target for AML. RNase R treatment 126 Total RNA (1 μg) of THP-1 was mixed with 4 U RNase R at 37℃ for 1 h. To 127 assess the stability of hsa_circ_0001947 and line AFF2 mRNA, the expression levels 128 were determined by using RT-PCR and agarose gel electrophoresis. 129 Oligonucleotide transfection 130 The sicirc, hsa-miR-329-5p mimics, hsa-miR-329-5p inhibitor and their related 131 control oligonucleotides were designed and synthesized by GenePharma (Shanghai, 132 China). The sequences were presented in as the candidate for the following study ( Fig. 1A) . The expression level of 203 hsa_circ_0058058 or hsa_circ_0001947 in the individual AML patients or healthy 204 control was shown by hierarchical clustering (Fig. 1B ). 205 We further validated the microarray results of the differential expression of 206 hsa_circ_0058058 and hsa_circ_0001947 in another cohort of 102 AML patients and 207 15 healthy controls by qRT-PCR. We found that the expression level of 208 hsa_circ_0001947 in newly diagnosed (median 0.0245, 0.00073-0.0947) or 209 relapsed-refractory AML patients (median 0.0133, 0.0018-0.1088) was much lower 210 compared to that in healthy controls (median 0.1015, 0.0276-0.2793, p < 0.0001). 211 Meanwhile, the expression level of hsa_circ_0001947 was elevated in patients 10 achieved complete remission (median 0.1058, 0.0067-0.4475, p<0.0001) compared to 213 that in the ND group (Fig. 1C ). However, the expression of hsa_circ_0058058 showed 214 no statistical difference between AML patients and controls ( Fig. 1D ). Therefore, 215 hsa_circ_0001947 was selected for the following functional study.
216
Characterization of hsa_circ_0001947 in AML 217 As the relationship between circRNA and linear RNA isoforms was complicated, 218 we also compared hsa_circ_0001947 and its linear isoform. According to circBase 219 database, we found that the spliced mature sequence of hsa_circ_0001947 was 220 derived from the exon of AFF2, whose length is 861bp ( Fig. 2A ). Moreover, we 221 confirmed the head-to-tail splicing structure in the qRT-PCR product of 222 hsa_circ_0001947 with the expected size by Sanger sequencing (Fig. 2B ). The 223 stability of hsa_circ_0001947 and AFF2 linear mRNA was further tested, and our 224 results showed that hsa_circ_0001947 harboring a loop structure was resistant to be 225 digested by RNase R, while AFF2 mRNA could be degraded ( Fig. 2C, D) . 226 As little is known about AFF2 mRNA in AML, we also determined the mRNA 227 expression of AFF2 in the same cohort of AML patients and healthy controls. Similar 228 with hsa_circ_0001947, we found the mRNA expression level of AFF2 was lower in 229 ND (median 0.0293, 0.0001-0.1276) or RE (median 0.0384, 0.0019-0.1118) AML 230 group and higher in control (median 0.0915, 0.0281-0.1358) or CR (median 0.1134, 231 0.0017-0.4005) group ( Fig. 2E ). Furthermore, a positive correlation between 232 hsa_circ_0001947 and AFF2 mRNA was observed in healthy controls or AML 233 patients at different stages ( Fig. 2F ).
234
Hsa_circ_0001947 is clinically favorable in AML patients 235 To explore the relationship between hsa_circ_0001947 and clinical practice, we 236 analyzed the clinical significance of the hsa_circ_0001947 in AML patients. We found 237 11 that the expression level of hsa_circ_0001947 was negatively correlated with white 238 blood cell (WBC) (r=-0.369, P<0.05) and positively linked to hemoglobin (HGB) in 239 AML patients (r=0.510, P<0.01) ( Fig. 3A, B ). Next, we analyzed the percentage of 240 primitive cells in bone marrow (BM%) or peripheral blood (PB%). The results 241 revealed that hsa_circ_0001947 expression level was negatively correlated with BM% 242 or PB% in AML patients (r=-0.496, P<0.01; r=-0.429, P<0.05, respectively) ( Fig.3C , 243 D). Associations between hsa_circ_0001947 and several AML clinical features are 244 shown in Table 3 , demonstrating no significant difference in the age, gender, 269 The area under the ROC curve (AUC) was used to determine the diagnostic 270 value of hsa_circ_0001947 for AML. The AUC of hsa_circ_0001947 at the ND stage 271 was 0.8911 (0.8103-0.9720, P <0.0001) ; the sensitivity and specificity were 93.33% 272 and 73.33% (Fig. 3G ). At the CR stage, the AUC of hsa_circ_0001947 was 0.9057 273 (0.8450-0.9664, P <0.0001) ; the sensitivity and specificity were 92.11% and 76.67% 274 ( Fig. 3H) . Meanwhile, the AUC of hsa_circ_0001947 at the RE stage was 0.7989 275 (0.5551-1.043, P <0.05) ; the sensitivity and specificity were 71.43% and 97.37% (Fig. 5B ). Then we dyed Annexin V and PI directly and found that the apoptotic 310 frequency of cells after transfecting the sicirc was lower than that of the siCtrl after 48 311 h. (Fig. 5C ). Further, the percentage of apoptotic cells were determined with Annexin 312 V and PI after treatment with 2 uM cytosine arabinoside (Ara-c). Apoptotic cells after 313 down-regulation of hsa_circ_0001947 was lower than that of control group (Fig. 5D ). 314 And then, in order to verify the candidate target gene, we conducted qRT-PCR in 315 THP-1 cells transfecting with sicirc/siCtrl, and the results revealed that the 316 downstream target gene CREBRF was also down-regulated after the 317 hsa_circ_0001947 down-regulation, which was in accordance with our prediction (Fig.   318 5E). 319 Next, we performed a dual-luciferase reporter assay to determine the direct target 320 gene of hsa-miR-329-5p based on their complementary sequences. A hsa-miR-329-5p 321 fragment was constructed. Then, we co-transfected a hsa-miR-329-5p mimics with the 322 reporter gene into 293T cells. A significant reduction in luciferase reporter activity 323 was observed relative to co-transfection with control RNA (Fig. 5F ). 324 What's more, to further determine the direct target gene relationship between 325 hsa-miR-329-5p and CREBRF, hsa-miR-329-5p mimics/nc and inhibitor/nc were 326 transfected into THP-1 cells. After applying the mimics, CREBRF expression 327 15 decreased compared with negative control, while after transfection with inhibitor, 328 CREBRF expression increased compared with negative control (Fig. 5G) . 329 Furthermore, qRT-PCR was performed to explore the CREBRF expression level in 330 AML specimens. Similar with hsa_circ_0001947 or AFF2, CREBRF mRNA 331 expression level was lower in ND (median 0.0150, 0.0018-0.0708) or RE (median 332 0.0212, 0.0120-0.0412) AML patients compared with control (median 0.0811, 333 0.0263-0.2349) or CR (median 0.0515, 0.0120-0.6329) group (Fig. 5H) . Moreover, in 334 matched bone marrow samples acquired from six AML patients, a significant increase 335 of hsa_circ_0001947 expression was demonstrated after achieving complete 336 remission (Fig. 5I ). results showed that transfecting hsa-miR-329-5p inhibitor could suppress the 343 proliferation of THP-1 cells compared with negative control. However, not much has 344 changed when mimics was applied (Fig. 6A, B) . Furthermore, the frequency of 345 apoptotic cells after transfecting hsa-miR-329-5p mimics was found lower than that of 346 the control group after treatment with 2 uM Ara-c for 48 h. Meanwhile, the percentage 347 of apoptotic cells after transfecting hsa-miR-329-5p inhibitor was elevated than that 348 of control group after treatment with 2 uM Ara-c for 48 h (Fig. 6C, D, E) . These 349 results suggest that hsa_circ_0001947 inhibits the proliferation and promotes 350 apoptosis in AML cell. Based on our results above, a detailed 351 circRNA-miRNA-mRNA (hsa_circ_0001947-hsa-miR-329-5p-CREBRF) interaction 352 network was presented for hsa_circ_0001947, allowing us to better understand its 353 underlying mechanisms for function in AML. 355 To explore the effects of hsa_circ_0001947 in vivo, THP-1 cells were injected 356 into the nude mice unilateral axilla (n=4 mice in each group). Our results showed that 357 the tumor volume in sicirc xenografts was bigger significantly than negative control 358 xenografts (326.21 ± 285.95 mm^3 versus 190.96 ± 192.37 mm^3) and tumor weight 359 were heavier in the sicirc group (Fig. 7A, B ). Next, we checked the expression of 360 hsa_circ_0001947 in tumor cells by RT-PCR. As shown in Figure 7C , the expression 361 of hsa_circ_0001947 and the target gene CREBRF was successfully downregulated, 362 as expected, but the linear gene AFF2 mRNA was not down-regulated in negative 363 control. This also indicates that we specifically down-regulated hsa_circ_0001947. In 364 addition, we also examined genes associated with proliferation and apoptosis. The 365 expression of Bcl-2 and c-Myc were elevated in sicirc tumor than negative control. 366 Moreover, Caspase-1 and Caspase-9 were reduced than negative control. Furthermore, 367 the percentage of apoptotic cells from the sicirc xenografts was lower than the cells 368 from negative control xenografts determined with Annexin V and PI (Fig. 7D ). Next, 369 we treated tumor cells with antibody Ki67 to compare the proliferation of the two 370 groups. Results revealed that the proliferation ratio of the sicirc group was 371 significantly higher than that of the negative control group (Fig. 7E ).
ROC curve analysis of hsa_circ_0001947 in AML patients
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Hsa_circ_0001947 inhibits AML cells proliferation and promotes apoptosis via
354
Hsa_circ_0001947 inhibits AML cells growth in vivo
372
Discussion
373
CircRNAs represent a widespread class of non-coding RNAs which are involved 374 in the pathogenesis of many diseases [22, 26, 27] , especially as important drivers of 375 tumorigenesis or tumor suppressors in distinct human cancers [28] . CircRNAs which 376 were regarded as miRNAs sponge have some characteristics in common. Through a 377 splicing mechanism called backsplices, the precursor of the RNA is spliced, and the 378 splicing donor connects to the upstream splicing receptor and forms circRNA [29] . 379 These circRNAs are predominantly located in the cytoplasm, which occupies the 380 same space of miRNAs [30] . CircRNAs with more predicting putative miRNAs 381 binding sites are likely to play the role of ceRNA for miRNAs [27] . However, the 382 function of circRNAs in the pathogenesis of AML has rarely been explored before. 383 Therefore, we intend to explore the role of circRNAs for the identification of potential 384 prognostic biomarkers or therapeutic targets for AML. 385 RNA sequencing or microarray analysis has been widely used to define the interactions between circRNAs and miRNAs. In our study, from the microarray 424 analysis and downstream bioinformatics analysis of the hsa_circ_0001947, we chose 425 hsa-miR-10b-3p, hsa-miR-329-5p and hsa-miR-488-3p as candidate miRNAs and 426 CREBRF, KLHL15, KRT12 and INTS9 as candidate target genes. To further verify 427 our prediction, we transfected mimics or inhibitor of predicted miRNAs into THP-1. 428 The expression level of CREBRF, which is a target of hsa_circ_0001947, was found 429 increased after inhibiting miRNAs. Luciferase assay further showed the precise and 430 authentic interactions between circRNAs and miRNA, and miRNA and targeted genes. 431 Finally, a detailed circRNA-miRNA-mRNA (hsa_circ_0001947-hsa-miR-329-5p-432 CREBRF) interaction network was presented for hsa_circ_0001947, allowing us to 433 better understand its underlying mechanisms for function in AML. Collectively, these 434 findings supported the hypothesis that hsa_circ_0001947 had an important role in 435 AML progression. 436 What's more, hsa-miR-329-5p gene has been predicted to be associated with 
